Meir Azulay

Title: Meir Azulay: Innovator in Antibody Therapies

Introduction

Meir Azulay is a prominent inventor based in Givatayim, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibody therapies. With a total of 2 patents, Azulay is recognized for his groundbreaking work in the medical research community.

Latest Patents

Azulay's latest patents focus on triple combination antibody therapies. The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies. This innovative approach aims to enhance the efficacy of cancer treatments by utilizing multiple mechanisms of action.

Career Highlights

Meir Azulay is currently associated with Compugen Ltd. Corporation, where he continues to push the boundaries of scientific research. His work has been instrumental in advancing therapeutic options for patients, particularly in oncology. His dedication to innovation has positioned him as a key figure in the biotechnology sector.

Collaborations

Azulay collaborates with talented professionals in his field, including Spencer Liang and Ling Leung. These partnerships foster a dynamic environment for research and development, leading to the creation of cutting-edge therapies.

Conclusion

Meir Azulay's contributions to antibody therapies exemplify the spirit of innovation in biotechnology. His work not only advances scientific knowledge but also holds the potential to improve patient outcomes in cancer treatment.